BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ADSs, and during the grace period, as may be extended, the Company's ADSs will continue to trade on Nasdaq under the symbol "BLRX".
In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until
In the event the Company does not regain compliance by
The Company will continue to monitor the closing bid price of its ADSs on Nasdaq between now and
If the Company cannot demonstrate compliance by the allotted compliance period(s), Nasdaq's staff will notify the Company that its ADSs are subject to delisting.
The Company is also listed on the Tel Aviv Stock Exchange and the notification letter does not affect the Company's compliance status with such listing.
About
Forward Looking Statement
Various statements in this release concerning
View original content:https://www.prnewswire.com/news-releases/biolinerx-announces-receipt-of-nasdaq-minimum-bid-price-notification-301668581.html
SOURCE
Contacts: United States, John Lacey, BioLineRx, +1-781-392-5514, johnl@biolinerx.com, Tim McCarthy, LifeSci Advisors, LLC, tim@lifesciadvisors.com, Israel, Moran Meir, LifeSci Advisors, LLC, +972-54-476-4945, moran@lifesciadvisors.com